These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene. Gharehbaghi K; Burgess GS; Collart FR; Litz-Jackson S; Huberman E; Jayaram HN; Boswell HS Leukemia; 1994 Aug; 8(8):1257-63. PubMed ID: 7520100 [TBL] [Abstract][Full Text] [Related]
23. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells. Gross AW; Ren R Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343 [TBL] [Abstract][Full Text] [Related]
24. Effects of transfection of p210bcr-abl and bcr-v-abl into the factor-dependent human leukemia cell line HSM-911. Takahashi M; Shigeno N; Takahashi H; Suzuki N; Masuko M; Nikkuni K; Toba K; Furukawa T; Aoki S; Kishi K; Koike T; Aizawa Y Leuk Res; 1997; 21(11-12):1115-23. PubMed ID: 9444946 [TBL] [Abstract][Full Text] [Related]
25. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice. Peters DG; Klucher KM; Perlingeiro RC; Dessain SK; Koh EY; Daley GQ Oncogene; 2001 May; 20(21):2636-46. PubMed ID: 11420675 [TBL] [Abstract][Full Text] [Related]
26. [Construction of eukaryotic expression vector of siRNA specific to bcr/abl fusion gene]. Xi YM; Liu T; Meng WT; Wang YH; Gu L; Lu XX; Gong YP Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jul; 36(4):460-3. PubMed ID: 16078560 [TBL] [Abstract][Full Text] [Related]
28. Baculovirus expression of functional P210 BCR-ABL oncogene product. Pendergast AM; Clark R; Kawasaki ES; McCormick FP; Witte ON Oncogene; 1989 Jun; 4(6):759-66. PubMed ID: 2499863 [TBL] [Abstract][Full Text] [Related]
29. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). Zhelev Z; Bakalova R; Ohba H; Ewis A; Ishikawa M; Shinohara Y; Baba Y FEBS Lett; 2004 Jul; 570(1-3):195-204. PubMed ID: 15251464 [TBL] [Abstract][Full Text] [Related]
30. BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac. Skorski T; Wlodarski P; Daheron L; Salomoni P; Nieborowska-Skorska M; Majewski M; Wasik M; Calabretta B Proc Natl Acad Sci U S A; 1998 Sep; 95(20):11858-62. PubMed ID: 9751755 [TBL] [Abstract][Full Text] [Related]
31. Human bcr-abl gene has a lethal effect on embryogenesis. Heisterkamp N; Jenster G; Kioussis D; Pattengale PK; Groffen J Transgenic Res; 1991 Dec; 1(1):45-53. PubMed ID: 1726940 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954 [TBL] [Abstract][Full Text] [Related]
33. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246 [TBL] [Abstract][Full Text] [Related]
34. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Pendergast AM; Muller AJ; Havlik MH; Maru Y; Witte ON Cell; 1991 Jul; 66(1):161-71. PubMed ID: 1712671 [TBL] [Abstract][Full Text] [Related]
35. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines. Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018 [TBL] [Abstract][Full Text] [Related]
36. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Sánchez-García I; Grütz G Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5287-91. PubMed ID: 7777499 [TBL] [Abstract][Full Text] [Related]
37. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Issaad C; Ahmed M; Novault S; Bonnet ML; Bennardo T; Varet B; Vainchenker W; Turhan AG Leukemia; 2000 Apr; 14(4):662-70. PubMed ID: 10764152 [TBL] [Abstract][Full Text] [Related]
38. Differential motility of p190bcr-abl- and p210bcr-abl-expressing cells: respective roles of Vav and Bcr-Abl GEFs. Daubon T; Chasseriau J; El Ali A; Rivet J; Kitzis A; Constantin B; Bourmeyster N Oncogene; 2008 Apr; 27(19):2673-85. PubMed ID: 18059343 [TBL] [Abstract][Full Text] [Related]